BMK Pharma is moving forward with a $50 million investment to build a 50,000‑square‑foot pharmaceutical manufacturing complex in Allen, Texas. The project, slated for completion in the summer of 2027, will combine sterile drug production, pharmaceutical development and contract manufacturing under one roof.
Location and Timeline
The new facility will sit near Exchange Parkway and U.S. Highway 75, a site chosen for its proximity to major transportation routes and a skilled local workforce. Construction is already under way, and city officials, including Mayor Chris Schulmeister, joined company representatives on Oct. 1 to mark progress at the site.
What the Plant Will Produce
BMK Pharma plans to operate a 503B outsourcing facility, allowing the production of compounded sterile medications for hospitals, clinics and other healthcare providers. The plant will focus on injectable drugs and other sterile dosage forms, adhering to U.S. Food and Drug Administration oversight and current Good Manufacturing Practices (cGMP). Automation and advanced manufacturing technology will be incorporated to increase efficiency and product quality.
Contract Development and Manufacturing Services
Beyond its own drug production, the Allen hub will offer contract development and manufacturing organization (CDMO) services. Pharmaceutical and biotechnology companies will be able to partner with BMK Pharma for development and scale‑up without needing to build their own facilities, expanding the region’s role in the national drug supply chain.
Economic Impact and Job Creation
The project is expected to support more than 100 high‑skilled positions across manufacturing, chemistry, engineering, automation, pharmacy and research. According to the Allen Economic Development Corporation, the city was selected for its strong talent pool, business‑friendly environment and active economic‑development support.
Strengthening Domestic Supply Chains
BMK Pharma’s leadership says the new plant will help improve medication availability, lower costs and reduce supply‑chain vulnerabilities by expanding U.S. production capacity. The focus on sterile injectable medications aligns with broader industry efforts to secure a reliable domestic supply of essential drugs.
Community Support
Founder Dr. Jay Bhaumik emphasized the company’s commitment to Allen, stating, “We are building the facility in Allen because we see tremendous room for opportunity here. Allen will become an important home for our pharmaceutical operations, and we are excited to continue investing in this community.” Local officials echoed this sentiment, highlighting the project’s contribution to Allen’s growing reputation as a hub for advanced manufacturing and technology‑focused businesses.
While a specific start‑up date for manufacturing has not been announced, the completion target of summer 2027 positions the facility to begin operations as the nation continues to seek stronger domestic pharmaceutical capabilities.
Original reporting: Local Profile (DFW) — read the source article.
